Abstract
The new "Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines Update on the Role of Neuropathology in the Management of Progressive Glioblastoma in Adults" was recently published in this journal. This was published using the 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System terminology. The wording for the new update on the role of neuropathology for progressive glioblastoma now warrants being updated to the new WHO 2021 classification of Tumors of the Central Nervous System to bring it into line with current parlance. The content of the WHO 2021 Classification of Tumors of the Central Nervous System terminology was reviewed to determine which components of the updated terminology for glioblastoma apply to the new guideline. Upon review of the content of the WHO 2021 Classification of Tumors of the Central Nervous System, "glioblastoma, IDH-wildtype WHO grade 4" was deemed closest to the tumors referred to as glioblastoma in the 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System terminology as used in the new guideline. The term "glioblastoma, IDH-wildtype WHO grade 4" was chosen for this update and substituted for "glioblastoma" in the questions and recommendations for the "Update on the Role of Neuropathology in the Management of Progressive Glioblastoma".
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
